Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

Significance: Relapsed/refractory DLBCL remains a major medical challenge, and most of these patients succumb to their disease. Here, we generated mouse models, faithfully recapitulating the biology of MYD88-driven human DLBCL. These models revealed robust preclinical activity of combined BTK/BCL2 inhibition. We confirmed activity of this regimen in pretreated non-GCB-DLBCL patients. See related commentary by Leveille et al., p. 8. This article is highlighted in the In This Issue feature, p. 1.

Citing Articles

Genetic Mouse Models of Lymphomas.

Knittel G, Reinhardt H Methods Mol Biol. 2024; 2865:411-428.

PMID: 39424735 DOI: 10.1007/978-1-0716-4188-0_18.

The Diverse Roles of ETV6 Alterations in B-Lymphoblastic Leukemia and Other Hematopoietic Cancers.

Monovich A, Gurumurthy A, Ryan R Adv Exp Med Biol. 2024; 1459:291-320.

PMID: 39017849 DOI: 10.1007/978-3-031-62731-6_13.

Dynamic immune status analysis of peripheral blood mononuclear cells in patients with bloodstream infection sepsis using single-cell RNA sequencing.

Zhang S, Zhang N, Han J, Sun Z, Jiang H, Huang W Front Immunol. 2024; 15:1380211.

PMID: 38898888 PMC: 11185935. DOI: 10.3389/fimmu.2024.1380211.

An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.

Prinz L, Riet T, Neureuther D, Lennartz S, Chrobok D, Hubbe H Cell Rep Med. 2024; 5(2):101421.

PMID: 38340727 PMC: 10897622. DOI: 10.1016/j.xcrm.2024.101421.

Mouse models of diffuse large B cell lymphoma.

Tabatabai A, Arora A, Hofmann S, Jauch M, von Tresckow B, Hansen J Front Immunol. 2023; 14:1313371.

PMID: 38124747 PMC: 10731046. DOI: 10.3389/fimmu.2023.1313371.

References

Holmes A, Corinaldesi C, Shen Q, Kumar R, Compagno N, Wang Z . Single-cell analysis of germinal-center B cells informs on lymphoma cell of origin and outcome. J Exp Med. 2020; 217(10). PMC: 7537389. DOI: 10.1084/jem.20200483. View

Wang J, Jeelall Y, Humburg P, Batchelor E, Kaya S, Yoo H . Synergistic cooperation and crosstalk between and mutations that dysregulate CD79B and surface IgM. J Exp Med. 2017; 214(9):2759-2776. PMC: 5584117. DOI: 10.1084/jem.20161454. View

Horwitz S, Negrin R, Blume K, Breslin S, Stuart M, Stockerl-Goldstein K . Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2003; 103(3):777-83. DOI: 10.1182/blood-2003-04-1257. View

Basso K, Dalla-Favera R . Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015; 15(3):172-84. DOI: 10.1038/nri3814. View

Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S, Schmitt A . NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. Biomedicines. 2018; 6(2). PMC: 6027339. DOI: 10.3390/biomedicines6020038. View

Torgovnick A, Heger J, Liaki V, Isensee J, Schmitt A, Knittel G . The Cdkn1a Mouse as a Tool to Study p53-Mediated Tumor Suppression. Cell Rep. 2018; 25(4):1027-1039.e6. DOI: 10.1016/j.celrep.2018.09.079. View

Shaffer A, Yu X, He Y, Boldrick J, Chan E, Staudt L . BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000; 13(2):199-212. DOI: 10.1016/s1074-7613(00)00020-0. View

Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini N . Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019; 3(11):1661-1669. PMC: 6560348. DOI: 10.1182/bloodadvances.2019000102. View

Kamdar M, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V . Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim.... Lancet. 2022; 399(10343):2294-2308. DOI: 10.1016/S0140-6736(22)00662-6. View

10.

Ye J, Ma N, Madden T, Ostell J . IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013; 41(Web Server issue):W34-40. PMC: 3692102. DOI: 10.1093/nar/gkt382. View

11.

Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, DAveni-Piney M . Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020; 4(22):5607-5615. PMC: 7686887. DOI: 10.1182/bloodadvances.2020003001. View

12.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

13.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

14.

Kochenderfer J, Yu Z, Frasheri D, Restifo N, Rosenberg S . Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. 2010; 116(19):3875-86. PMC: 2981541. DOI: 10.1182/blood-2010-01-265041. View

15.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

16.

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

17.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D . TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020; 182(2):297-316.e27. PMC: 7384961. DOI: 10.1016/j.cell.2020.05.049. View

18.

Lenz G, Nagel I, Siebert R, Roschke A, Sanger W, Wright G . Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007; 204(3):633-43. PMC: 2137913. DOI: 10.1084/jem.20062041. View

19.

Schmidt-Supprian M, Wunderlich F, Rajewsky K . Excision of the Frt-flanked neo (R) cassette from the CD19cre knock-in transgene reduces Cre-mediated recombination. Transgenic Res. 2007; 16(5):657-60. DOI: 10.1007/s11248-007-9100-4. View

20.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View